A pandemic influenza H1N1 live vaccine based on modified vaccinia ankara is highly immunogenic and protects mice in active and passive immunizations

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Hessel, Annett ^a   Schwendinger, Michael ^a   Fritz, Daniela ^a   Coulibaly, Sogue ^a   Holzer, Georg W ^a   Sabarth, Nicolas ^a   Kistner, Otfried ^a   Wodal, Walter ^a   Kerschbaum, Astrid ^a   Savidis Dacho, Helga ^a   Crowe, Brian A ^a   Kreil, Thomas R ^a   Barrett, P Noel ^a   Falkner, Falko G ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; MODIFIED VACCINIA VIRUS ANKARA INFLUENZA A (H1N1) VACCINE; NEUTRALIZING ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG; H1N1 VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICK EMBRYO; CONTROLLED STUDY; EMBRYO; FEMALE; GENE INSERTION; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; INFLUENZA A (H1N1); KIDNEY CELL; LUNG INFECTION; LUNG PARENCHYMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PASSIVE IMMUNIZATION; PROTECTION; SINGLE DRUG DOSE; SPLEEN; VERO CELL; VIRUS INHIBITION; VIRUS STRAIN; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; CELL LINE; CROSS REACTION; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; LUNG; METHODOLOGY; VACCINATION;

ANIMALIA; MUS; ORTHOMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CROSS REACTIONS; DISEASE OUTBREAKS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCOMPETENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; NEURAMINIDASE; SPLEEN; VACCINATION; VACCINES, ATTENUATED;

EID: 77957865632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012217     Document Type: Article

References (40)

1. Yen HL, Webster RG (2009) Pandemic influenza as a current threat. Curr Top Microbiol Immunol 333: 3-24.
2. Wright PF, Neumann G, Kawaoka Y, eds. Orthomyxoviruses. Fields Virology, 5th Edition: Lippincott Williams & Wilkins. pp 1692-1740.
3. Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 842-847.
4. Maassab HF, Bryant ML (1999) The development of live attenuated coldadapted influenza virus vaccine for humans. Rev Med Virol 9: 237-244.
5. Alexandrova GI, Polezhaev FI, Budilovsky GN, Garmashova LM, Topuria NA, et al. (1984) Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun 44: 734-739.
6. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, et al. (2000) Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A 97: 4309-4314.
7. Palese P, Muster T, Zheng H, O'Neill R, Garcia-Sastre A (1999) Learning from our foes: a novel vaccine concept for influenza virus. Arch Virol Suppl 15: 131-138.
8. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, et al. (2009) Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27: 4953-4960.
9. Suguitan AL, Jr., Marino MP, Desai PD, Chen LM, Matsuoka Y, et al. (2009) The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 395: 280-288.
10. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, et al. (2002) Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 76: 7713-7723.
11. Scheiflinger F, Dorner F, Falkner FG (1998) Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 143: 467-474.
12. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
13. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 (Pt 5): 1031-1038.
14. Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, et al. (1998) Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249: 160-166.
15. Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK (1998) The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 248: 295-304.
16. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, et al. (2010) A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 5: e9349.
17. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
18. WHO (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance. Rev.1 ed.
19. Sandbulte MR, Gao J, Straight TM, MC E (2009) A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics- derived antigens. Influenza and other respiratory Viruses 3: 233-240.
20. Wyatt LS, Shors ST, Murphy BR, Moss B (1996) Development of a replicationdeficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
21. Yuen L, Moss B (1987) Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A 84: 6417-6421.
22. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484-487.
23. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, et al. (2007) Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195: 1598-1606.
24. Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, et al. (2009) MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 4: e7790.
25. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Preclinical evaluation of a modified vaccinia virus Ankara (MVA)- based vaccine against influenza A/H5N1 viruses. Vaccine 27: 6296-6299.
26. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199: 405-413.
27. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol 83: 5192-5203.
28. Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, et al. (2009) Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 182: 3063-3071.
29. Kilbourne ED, Laver WG, Schulman JL, Webster RG (1968) Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2: 281-288.
30. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160: 322-327.
31. Yap KL, Ada GL (1978) The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol 8: 413-420.
32. Seo SH, Peiris M, Webster RG (2002) Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76: 4886-4890.
33. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006) CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211: 8-22.
34. Cerwenka A, Morgan TM, Dutton RW (1999) Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol 163: 5535-5543.
35. Lawrence CW, Ream RM, Braciale TJ (2005) Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174: 5332-5340.
36. McGill J, Legge KL (2009) Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol 183: 4177-4181.
37. Williams SP, Robertson JS (1993) Analysis of the restriction to the growth of nonegg-adapted human influenza virus in eggs. Virology 196: 660-665.
38. Gubareva LV, Wood JM, Meyer WJ, Katz JM, Robertson JS, et al. (1994) Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology 199: 89-97.
39. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74: 7651-7655.
40. Scherle PA, Palladino G, Gerhard W (1992) Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol 148: 212-217.